Clinical Trial Supplies: A Fast-Growing Market Built On Logistics

By Priyank Tiwari, Head of Global Partner Relations and Business Development, MarketsandMarkets

Every clinical trial depends on a physical product reaching the right site, or the right patient's home, in the right condition and at the right time. The industry that makes this possible is smaller than the CRO and drug-development sectors around it, but it is growing quickly as trials become more global, more complex, and more patient-centric. This article draws on MarketsandMarkets research to outline the size of the market, where revenue is concentrated, what is driving growth, and how competition is changing.

Market Size And Outlook

According to MarketsandMarkets' latest edition, the clinical trial supplies market is projected to grow from USD 5.60 billion in 2026 to USD 8.95 billion by 2031, a compound annual growth rate (CAGR) of 8.9%. The previous edition valued the market at USD 5.34 billion in 2025, heading to USD 8.18 billion by 2030, also at an 8.9% CAGR. The growth rate has held steady across editions; the newer one simply moves the base year forward.

MarketsandMarkets have followed this market for several years. An earlier edition estimated it at USD 3.9 billion in 2023, reaching USD 6.3 billion by 2028 at a CAGR of 9.9%. Taken together, the editions describe a market that consistently expanded, at roughly 9% to 10% a year. That consistency suggests demand is structural rather than cyclical, tied to the steady rise in trial volume and complexity.

What The Market Covers

The report segments the market by service, trial phase, product type, and end user. Services include manufacturing, sourcing, packaging, labelling, and logistics. The ecosystem spans raw material suppliers such as packaging vendors, cold chain providers, and labeling firms, along with supply manufacturers and service firms. End users include pharmaceutical sponsors, contract research organizations (CROs), hospitals, and site networks.

Where The Revenue Sits

Logistics leads. Logistics and distribution held the largest share of the market, at 27.2% in 2025. Moving temperature-sensitive products across borders and through depots to clinical represents the market’s largest revenue segment.

Phase III dominates; Phase II is catching up. Phase III led the market in 2024 because of its large-scale patient recruitment and extensive supply chain needs. Phase II is expected to grow at a significant rate as more drug candidates move from preclinical work into early-stage trials.

Small molecules still lead by type. The small molecules segment dominated in 2024, reflecting the continued weight of conventional drug development in trial pipelines.

North America leads; Asia Pacific is rising. North America dominated in 2025, helped by its strong pharma and biotech base, high R&D investment, and established trial infrastructure. MarketsandMarkets expects Asia Pacific to be the fastest-growing region over the forecast period.

What Is Driving Growth

MarketsandMarkets identifies several forces behind the 8.9% outlook.

Global, multicenter trials. The expansion of trials across many countries is a key driver of demand. More studies in diverse geographies raise the need for efficient global logistics and region-specific regulatory expertise.

Decentralized trials. The growing number of decentralized clinical trials is expected to create lucrative opportunities. Home delivery of trial drugs, digital tracking, and direct-to-patient supply are reshaping how supply strategies are built, because every participant can become a delivery destination rather than a hospital pharmacy.

Outsourcing. Pharma and biotech companies increasingly hand trial operations to specialists, and the CRO and CDMO segment is expected to grow at a significant rate as a result.

Regulation and waste. Tighter regulatory requirements, rising trial complexity, and inefficiencies such as overproduction and wastage all push sponsors toward more disciplined, better-planned supply models.

The Main Restraint: Cost

The picture is not uniformly positive. MarketsandMarkets flags that the high cost of clinical trial supplies restrains growth, because supplies weigh heavily on overall trial budgets. That pressure is one reason sponsors are looking for providers that can cut waste and consolidate services. Providers that can show measurable savings will have an edge.

A Moderately Consolidated Field

The report names Almac Group, Novo Holdings, Marken (UPS), PCI Pharma Services, Sharp Services, Thermo Fisher Scientific, Cencora, Myonex, Clinigen, Inceptua Group, and Eurofins Scientific among the leading companies. The top five players collectively hold an estimated 25% to 30% of the market, which makes the structure moderately consolidated but still competitive.

The way customers buy is also changing. MarketsandMarkets observes a gradual shift from fragmented, transaction-based purchasing of packaging, storage, and transport toward integrated, end-to-end supply models. Investment is flowing into integrated packaging, labeling, storage, cold-chain transportation, depot networks, and digital shipment visibility. The company's strategic outlook makes the same point: vendors offering end-to-end solutions, from packaging and labeling to logistics and regulatory consulting, are positioned to capture significant share.

What This Mean For Sponsors And Clinical Supply Teams

The figures above describe the market. The practical question for pharmaceutical and biotech sponsors is what to do differently as a result. The takeaways below are our interpretation of MarketsandMarkets' findings, not statements from the report itself.

What To Expect Over The Next 3 To 5 Years

Clinical supply operations are likely to move from a series of separate purchases toward managed, end-to-end programs. MarketsandMarkets points to a shift away from fragmented, transaction-based buying of packaging, storage, and transport, and to the strong growth expected in Phase II, which means more early-stage programs competing for supply capacity. Supply teams should expect to be brought into protocol design earlier, to manage more data across more partners, and to be judged on visibility and waste as well as on-time delivery. With the market growing close to 9% a year, capacity at leading providers may tighten, so early planning and booking will matter.

Complexity, Decentralization, And Global Expansion

Complex protocols. More complex designs typically mean more kit configurations, comparators, and country-specific labeling. Supply plans need to be tested against scenarios such as faster or slower enrollment and protocol amendments before the first shipment, not after.

Decentralized trials. When a participant's home becomes the delivery point, shipments become smaller, more numerous, and harder to track. Sponsors should plan for patient-level chain of custody, temperature monitoring, and home-delivery rules that vary by country.

Global expansion. Multicenter trials across more geographies raise the need for regional regulatory expertise, import and export planning, and depots close enough to sites to keep lead times workable. Sponsors adding sites in Asia Pacific, the region MarketsandMarkets expect to grow fastest, should check depot and courier coverage early.

Challenges To Anticipate Cost, Waste, Inventory, And Distribution

Cost. MarketsandMarkets identifies the high cost of supplies as a restraint on the market because of its weight in trial budgets. Budgets should treat cold chain, direct-to-patient delivery, and global distribution as major line items from the start.

Waste. Overproduction and wastage are named as industry inefficiencies. Generous overage buffers protect against stock-outs but leave expired product behind, so forecasting needs to be refreshed as the trial runs rather than fixed at the outset.

Inventory. More depots and more patient-level shipments make it harder to see where stock sits. Without real-time inventory data, teams tend to over-order to stay safe.

Distribution. Temperature excursions, customs delays, and last-mile failures grow more likely as networks widen. Contingency plans and clear responsibilities for deviations should be agreed with partners in advance.

Rethinking Outsourcing And Integrated Supply

Outsourcing is set to continue, and MarketsandMarkets expect the CRO and CDMO segment to grow at a significant rate. Integrated models, where one provider handles packaging, labeling, storage, and distribution, can reduce handoffs and improve visibility. They also bring trade-offs, including dependence on a single partner and less flexibility if needs change midstream.

Sponsors weighing this choice should compare providers on digital shipment visibility, depot networks that match the planned site footprint, regulatory expertise in target regions, and proven direct-to-patient capability, not on unit price alone. A hybrid approach, with an integrated core partner and a specialist for niche needs such as ultra-cold or patient delivery, may suit some programs. Because the top five players hold only an estimated 25% to 30% of the market, sponsors have real choice.

Operational Decisions for Clinical Supply Teams

For clinical supply teams, the key is translating these market shifts into decisions about planning, forecasting, partner selection, and distribution strategy.

1. Involve supply early. Bring clinical supply into protocol design so complexity, comparators, and geography are reflected in the plan from day one.
2. Forecast continuously. Replace one-time demand estimates with regular reforecasting tied to actual enrollment and site activation.
3. Choose partners for integration and visibility. Weigh data access and network fit alongside price.
4. Build direct-to-patient capability deliberately. Pilot in selected countries before scaling and confirm local regulatory requirements first.
5. Track waste and inventory as performance measures. What gets reported gets managed, and the cost restraint makes this hard to ignore.
6. Plan regionally. Treat Asia Pacific and other growth regions as distinct supply environments rather than extensions of existing networks.

About The Author:

Priyank Tiwari is the Head of Global Partner Relations and Business Development at MarketsandMarkets, where he leads strategic partnerships and sales initiatives that generate USD 6 million in annual revenue through content aggregators and channel partners. He has been instrumental in building partnerships with global media houses and event management firms, strengthening brand visibility and market awareness. His experience spans healthcare, life sciences, biotechnology, ICT, semiconductors and electronics, and food and beverage. With strong sales expertise, entrepreneurial thinking, and a results-driven approach, Priyank oversees the end-to-end sales conversion process for qualified leads across inbound and outbound channels.